SPRUCE BIOSCIENCES INC (SPRB) Stock Price, Quote, News and Overview
NASDAQ:SPRB - Nasdaq - US85209E1091 - Common Stock - Currency: USD
SPRB Quote, Performance and Key Statistics
0.1187
0 (-3.5%)
The current stock price of SPRB is 0.1187 USD. In the past month the price decreased by -64.67%. In the past year, price decreased by -83.05%.
SPRB Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.09 | 306.02B | ||
| AMGN | AMGEN INC | 13.99 | 149.08B | ||
| GILD | GILEAD SCIENCES INC | 22.68 | 130.32B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1686.55 | 125.74B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.34 | 61.56B | ||
| ARGX | ARGENX SE - ADR | 318.82 | 36.23B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 30.51B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.74B | ||
| NTRA | NATERA INC | N/A | 20.02B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.15B | ||
| BIIB | BIOGEN INC | 7.2 | 17.36B |
Related stock screener links
About SPRB
Company Profile
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. The company is headquartered in South San Francisco, California and currently employs 22 full-time employees. The company went IPO on 2020-10-09. The firm is initially developing its wholly owned product candidate, Tildacerfont, as the potential first non-steroidal therapy for patients suffering from classic congenital adrenal hyperplasia (CAH). The company is also developing Tildacerfont for females suffering from polycystic ovary syndrome (PCOS). The company has initiated CAHmelia-203, a placebo-controlled, double-blind Phase IIb clinical trial in adult patients with classic CAH with elevated levels of androstenedione (A4) at baseline. The company has also initiated CAHmelia-204, a second Phase IIb clinical trial in adult patients with classic CAH on supraphysiologic doses of glucocorticoids with normal or near normal levels of A4 at baseline focused on glucocorticoid reduction. The firm also investigates tildacerfont for the treatment of classic CAH in children.
Company Info
SPRUCE BIOSCIENCES INC
611 Gateway Boulevard, Suite 740
South San Francisco CALIFORNIA 94104 US
CEO: Richard King
Employees: 22
Company Website: https://sprucebio.com/
Investor Relations: https://investors.sprucebiosciences.com/
Phone: 14156554168
SPRUCE BIOSCIENCES INC / SPRB FAQ
What is the stock price of SPRUCE BIOSCIENCES INC today?
The current stock price of SPRB is 0.1187 USD. The price decreased by -3.5% in the last trading session.
What is the ticker symbol for SPRUCE BIOSCIENCES INC stock?
The exchange symbol of SPRUCE BIOSCIENCES INC is SPRB and it is listed on the Nasdaq exchange.
On which exchange is SPRB stock listed?
SPRB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SPRUCE BIOSCIENCES INC stock?
10 analysts have analysed SPRB and the average price target is 1.87 USD. This implies a price increase of 1475.37% is expected in the next year compared to the current price of 0.1187. Check the SPRUCE BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SPRUCE BIOSCIENCES INC worth?
SPRUCE BIOSCIENCES INC (SPRB) has a market capitalization of 4.90M USD. This makes SPRB a Nano Cap stock.
How many employees does SPRUCE BIOSCIENCES INC have?
SPRUCE BIOSCIENCES INC (SPRB) currently has 22 employees.
Is SPRUCE BIOSCIENCES INC (SPRB) expected to grow?
The Revenue of SPRUCE BIOSCIENCES INC (SPRB) is expected to decline by -40.59% in the next year. Check the estimates tab for more information on the SPRB EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy SPRUCE BIOSCIENCES INC (SPRB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SPRB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SPRB, evaluating the profitability, health, valuation and growth aspects
- SPRUCE BIOSCIENCES INC (SPRB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SPRUCE BIOSCIENCES INC (SPRB) Sales and EPS estimates to see what analysts future expectations are.
- SPRUCE BIOSCIENCES INC (SPRB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SPRUCE BIOSCIENCES INC (SPRB) Insider and Institutional Ownership to learn about the owners and their transactions.
- SPRUCE BIOSCIENCES INC (SPRB) Stock Chart to make your own analysis
- SPRUCE BIOSCIENCES INC (SPRB) Latest news and press-releases to stay up to date.
Does SPRUCE BIOSCIENCES INC (SPRB) stock pay dividends?
SPRB does not pay a dividend.
When does SPRUCE BIOSCIENCES INC (SPRB) report earnings?
SPRUCE BIOSCIENCES INC (SPRB) will report earnings on 2025-05-12, after the market close.
What is the Price/Earnings (PE) ratio of SPRUCE BIOSCIENCES INC (SPRB)?
SPRUCE BIOSCIENCES INC (SPRB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.95).
What is the Short Interest ratio of SPRUCE BIOSCIENCES INC (SPRB) stock?
The outstanding short interest for SPRUCE BIOSCIENCES INC (SPRB) is 1.16% of its float. Check the ownership tab for more information on the SPRB short interest.
SPRB Technical Analysis
SPRB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to SPRB. SPRB may be in some trouble as it scores bad on both profitability and health.
SPRB Financial Highlights
Over the last trailing twelve months SPRB reported a non-GAAP Earnings per Share(EPS) of -0.95. The EPS increased by 36.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -60.56% | ||
| ROE | -76.35% | ||
| Debt/Equity | 0.01 |
SPRB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 50% to SPRB. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 24.39% and a revenue growth -40.59% for SPRB